Annual Cash & Cash Equivalents
$113.02 M
+$47.44 M+72.34%
31 December 2023
Summary:
Cytokinetics Incorporated annual cash & cash equivalents is currently $113.02 million, with the most recent change of +$47.44 million (+72.34%) on 31 December 2023. During the last 3 years, it has risen by +$30.04 million (+36.20%). CYTK annual cash & cash equivalents is now -9.73% below its all-time high of $125.21 million, reached on 31 December 2017.CYTK Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$46.89 M
-$143.25 M-75.34%
30 September 2024
Summary:
Cytokinetics Incorporated quarterly cash and cash equivalents is currently $46.89 million, with the most recent change of -$143.25 million (-75.34%) on 30 September 2024. Over the past year, it has dropped by -$52.80 million (-52.97%). CYTK quarterly cash and cash equivalents is now -76.65% below its all-time high of $200.81 million, reached on 30 September 2020.CYTK Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CYTK Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +72.3% | -53.0% |
| 3 y3 years | +36.2% | -48.2% |
| 5 y5 years | +167.5% | +18.3% |
CYTK Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +72.3% | -75.3% | at low |
| 5 y | 5 years | at high | +210.2% | -76.7% | +28.7% |
| alltime | all time | -9.7% | +928.3% | -76.7% | +425.9% |
Cytokinetics Incorporated Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $46.89 M(-75.3%) |
| June 2024 | - | $190.14 M(+58.5%) |
| Mar 2024 | - | $119.98 M(+6.2%) |
| Dec 2023 | $113.02 M(+72.3%) | $113.02 M(+13.4%) |
| Sept 2023 | - | $99.69 M(+45.2%) |
| June 2023 | - | $68.64 M(-32.5%) |
| Mar 2023 | - | $101.62 M(+54.9%) |
| Dec 2022 | $65.58 M(-41.8%) | $65.58 M(-38.3%) |
| Sept 2022 | - | $106.24 M(+13.5%) |
| June 2022 | - | $93.63 M(-18.9%) |
| Mar 2022 | - | $115.42 M(+2.4%) |
| Dec 2021 | $112.67 M(+35.8%) | $112.67 M(+24.4%) |
| Sept 2021 | - | $90.56 M(+143.7%) |
| June 2021 | - | $37.15 M(-16.7%) |
| Mar 2021 | - | $44.59 M(-46.3%) |
| Dec 2020 | $82.98 M(+127.8%) | $82.98 M(-58.7%) |
| Sept 2020 | - | $200.81 M(+228.5%) |
| June 2020 | - | $61.13 M(+22.8%) |
| Mar 2020 | - | $49.78 M(+36.6%) |
| Dec 2019 | $36.43 M(-13.8%) | $36.43 M(-8.1%) |
| Sept 2019 | - | $39.63 M(+15.3%) |
| June 2019 | - | $34.36 M(-12.8%) |
| Mar 2019 | - | $39.41 M(-6.7%) |
| Dec 2018 | $42.26 M(-66.3%) | $42.26 M(+53.0%) |
| Sept 2018 | - | $27.62 M(-41.2%) |
| June 2018 | - | $46.95 M(-59.2%) |
| Mar 2018 | - | $115.01 M(-8.1%) |
| Dec 2017 | $125.21 M(+87.2%) | $125.21 M(+7.6%) |
| Sept 2017 | - | $116.32 M(+15.5%) |
| June 2017 | - | $100.71 M(+104.0%) |
| Mar 2017 | - | $49.36 M(-26.2%) |
| Dec 2016 | $66.87 M(+2.8%) | $66.87 M(+120.7%) |
| Sept 2016 | - | $30.30 M(+9.3%) |
| June 2016 | - | $27.72 M(-34.4%) |
| Mar 2016 | - | $42.27 M(-35.0%) |
| Dec 2015 | $65.08 M(+221.9%) | $65.08 M(+150.7%) |
| Sept 2015 | - | $25.96 M(+4.5%) |
| June 2015 | - | $24.84 M(+10.2%) |
| Mar 2015 | - | $22.55 M(+11.5%) |
| Dec 2014 | $20.21 M | $20.21 M(+56.6%) |
| Sept 2014 | - | $12.91 M(+4.5%) |
| June 2014 | - | $12.36 M(-6.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $13.26 M(-34.2%) |
| Dec 2013 | $20.16 M(+35.2%) | $20.16 M(+4.7%) |
| Sept 2013 | - | $19.26 M(+12.9%) |
| June 2013 | - | $17.06 M(+29.6%) |
| Mar 2013 | - | $13.16 M(-11.7%) |
| Dec 2012 | $14.91 M(-20.8%) | $14.91 M(-3.1%) |
| Sept 2012 | - | $15.39 M(-75.8%) |
| June 2012 | - | $63.65 M(+257.3%) |
| Mar 2012 | - | $17.82 M(-5.4%) |
| Dec 2011 | $18.83 M(+7.5%) | $18.83 M(+1.3%) |
| Sept 2011 | - | $18.59 M(-21.8%) |
| June 2011 | - | $23.77 M(+53.8%) |
| Mar 2011 | - | $15.45 M(-11.8%) |
| Dec 2010 | $17.51 M(-31.5%) | $17.51 M(-42.5%) |
| Sept 2010 | - | $30.44 M(+65.7%) |
| June 2010 | - | $18.36 M(-11.3%) |
| Mar 2010 | - | $20.71 M(-19.0%) |
| Dec 2009 | $25.56 M(-38.9%) | $25.56 M(+7.8%) |
| Sept 2009 | - | $23.71 M(-72.1%) |
| June 2009 | - | $85.03 M(+75.4%) |
| Mar 2009 | - | $48.49 M(+15.9%) |
| Dec 2008 | $41.82 M(-64.1%) | $41.82 M(-40.8%) |
| Sept 2008 | - | $70.64 M(-18.7%) |
| June 2008 | - | $86.86 M(-17.7%) |
| Mar 2008 | - | $105.54 M(-9.5%) |
| Dec 2007 | $116.56 M(+195.9%) | $116.56 M(+7.4%) |
| Sept 2007 | - | $108.49 M(-2.5%) |
| June 2007 | - | $111.22 M(+6.9%) |
| Mar 2007 | - | $104.05 M(+164.2%) |
| Dec 2006 | $39.39 M(+191.4%) | $39.39 M(-18.3%) |
| Sept 2006 | - | $48.21 M(-3.1%) |
| June 2006 | - | $49.77 M(-31.9%) |
| Mar 2006 | - | $73.11 M(+441.0%) |
| Dec 2005 | $13.52 M(+3.5%) | $13.52 M(+14.5%) |
| Sept 2005 | - | $11.80 M(+8.2%) |
| June 2005 | - | $10.91 M(-26.4%) |
| Mar 2005 | - | $14.82 M(+13.4%) |
| Dec 2004 | $13.06 M(+18.8%) | $13.06 M(-34.0%) |
| Sept 2004 | - | $19.77 M(+12.0%) |
| June 2004 | - | $17.65 M(+98.0%) |
| Mar 2004 | - | $8.92 M(-18.9%) |
| Dec 2003 | $10.99 M(-32.9%) | $10.99 M |
| Dec 2002 | $16.39 M | - |
FAQ
- What is Cytokinetics Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated annual cash & cash equivalents year-on-year change?
- What is Cytokinetics Incorporated quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated quarterly cash and cash equivalents year-on-year change?
What is Cytokinetics Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of CYTK is $113.02 M
What is the all time high annual cash & cash equivalents for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high annual cash & cash equivalents is $125.21 M
What is Cytokinetics Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, CYTK annual cash & cash equivalents has changed by +$47.44 M (+72.34%)
What is Cytokinetics Incorporated quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CYTK is $46.89 M
What is the all time high quarterly cash and cash equivalents for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high quarterly cash and cash equivalents is $200.81 M
What is Cytokinetics Incorporated quarterly cash and cash equivalents year-on-year change?
Over the past year, CYTK quarterly cash and cash equivalents has changed by -$52.80 M (-52.97%)